BIOCON stock
BIOCON is showing a constructive news setup around Biotechnology, with 6 recent stories and improving sentiment breadth.
BIOCON has built a constructive coverage cluster in the last 27 days. The strongest recurring theme is Biotechnology, while the current weighted impact score is +42 from 5 bullish, 0 bearish, and 1 neutral stories across 4 sources.
BIOCON is last saved at ₹402.1 with a day move of +0.00%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
Biocon's latest financial report shows the company earned Rs 3821.4 crore in revenue and made a profit of Rs 81.1 crore. This filing is on record. These numbers show how much money the company made and kept, which helps you understand its financial health. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 6 days ago · 2 min read
Economic Times · 13 days ago · 2 min read
Economic Times · 17 days ago · 2 min read
Mint · 24 days ago · 2 min read
Mint · 26 days ago · 2 min read
How BIOCON stacks against related names in this news cluster
BIOCON has appeared across 6 recent stories from 4 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
BIOCON coverage is currently leaning bullish, with 5 bullish, 0 bearish, and 1 neutral analyzed stories in the recent window.
Recent BIOCON coverage is clustering around Biotechnology and Pharmaceuticals. Related names showing up alongside BIOCON include CUMMINSIND, PBFINTECH, POWERGRID.
Use this page as a coverage hub for BIOCON: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
3 recent mentions linked to BIOCON
TopicPharmaceuticals3 recent mentions linked to BIOCON
StockCUMMINSINDRelated news cluster with 1 links
Latest storyBullish for BIOCON: Japan Nod for Pegfilgrastim Biosimilar BoostsRegulatory approvals, especially in developed markets like Japan, are key catalysts for Indian pharm
How retail crowds and channels are talking about BIOCON right now — context for your own research, not a trade call.